MedTrace Logo

Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia

NCT04222855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-01-10

No results posted yet for this study

Summary

Both preeclampsia and eclampsia are important health problems, being an important cause of maternal death in the world.

Nifedipine has been used as the drug of choice for the treatment of hypertension during puerperium for more than 25 years.

Diltiazem is an alternative calcium antagonist that is 1000 times less potent than nifedipine.

There are no reports in the literature, no randomized clinical trials that prove the effectiveness of diltiazem for the control of blood pressure in post-partum patients with severe preeclampsia.

Conditions

  • Postpartum Preeclampsia

Interventions

DRUG

Diltiazem

Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).

Sponsors & Collaborators

  • Ocharan-Hernández, Esther, MD, PhD

    collaborator UNKNOWN

  • Vargas-De-León, Cruz, MSc

    collaborator UNKNOWN

  • Calzada-Mendoza, Claudia, PhD

    collaborator UNKNOWN

  • Hospital de la Mujer

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-01
Primary Completion
2009-05-30
Completion
2009-05-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04222855 on ClinicalTrials.gov